Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more manufacturing capacity.

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

The Fed has emphasized that tariff-related inflation is likely transitory. Futures markets anticipate two interest rate cuts this year, with a 50% chance of a third, sparking demand in Treasury ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...